Kura Oncology (KURA) announced that on August 1, 2025, the Compensation Committee of the Company’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 646,700 shares of common stock to thirty-five (35) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology Partners with Kyowa Kirin for Ziftomenib
- Promising Developments in Kura Oncology’s AML Treatment Drive Buy Rating
- Optimistic Outlook on Kura Oncology: Promising Developments in AML Treatment with Ziftomenib
- Kura Oncology Announces Positive Phase 1a/1b Trial Results